Cargando…
Stopping antibiotic therapy after 72 h in patients with febrile neutropenia following intensive chemotherapy for AML/MDS (safe study): A retrospective comparative cohort study
BACKGROUND: Induction chemotherapy for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) is almost universally complicated by febrile neutropenia(FN). Empirical broad-spectrum antibiotic therapy (EBAT) strategies advocated by guidelines result in long periods of broad-spectrum antibioti...
Autores principales: | Schauwvlieghe, A., Dunbar, A., Storme, E., Vlak, A., Aerts, R., Maertens, J., Sciot, B., Van Der Wel, T., Papageorgiou, G., Moors, I., Cornelissen, J.J., Rijnders, B.J.A., Mercier, T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099620/ https://www.ncbi.nlm.nih.gov/pubmed/33997746 http://dx.doi.org/10.1016/j.eclinm.2021.100855 |
Ejemplares similares
-
Severe congenital neutropenia, a genetically heterogeneous disease group with an increased risk of AML/MDS
por: Vandenberghe, Peter, et al.
Publicado: (2011) -
Point of care aspergillus testing in intensive care patients
por: Mercier, Toine, et al.
Publicado: (2020) -
IRAK1: oncotarget in MDS and AML
por: Beverly, Levi J., et al.
Publicado: (2014) -
Inherited predisposition to MDS/AML
por: Rio Machin, Ana, et al.
Publicado: (2018) -
Prescribing Empiric Antibiotics for Febrile Neutropenia: Compliance with Institutional Febrile Neutropenia Guidelines
por: Naeem, Doaa, et al.
Publicado: (2018)